Genomma Lab Internacional, S.A.B. de C.V. Announces Management Changes
November 28, 2022 at 01:53 am EST
Share
Genomma Lab Internacional, S.A.B. de C.V. announced a leadership succession plan that positions the Company to continue driving profitable growth and delivering on the Company's vision, as CEO Jorge Brake has informed the Board of his intention to transition from the CEO role while maintaining active involvement in the Company's future. Mr. Brake will be appointed Active Vice Chairman of the Board of Directors, pending approval at Genomma's next Annual General Shareholders Meeting to be held in April 2023. Mr. Brake, in his ongoing role as Active Vice Chairman, will remain actively involved in the Company's strategic direction, corporate external relations, investor relations, new business opportunities and expansion, as well as the next phase of Genomma's organizational transformation with important related oversight and involvement in shaping the Company's future direction.
Further, he will remain involved in mentoring and counselling Genomma's operating executives as they develop within the Company. He will also actively participate in relevant company decisions as member of several Executive Committees that have been approved by the Board of Directors as part of Genomma's renewed Governance Model. Following Brake's appointment as CEO in 2018, he set in motion a profound strategic and cultural transformation anchored on evolving to a growth mindset while leveraging Genomma's talent to drive growth as a cohesive team.
His leadership has been a critical factor to Genomma's achieving significant milestones and to the Company's successful turnaround as a renewed multinational enterprise which is well positioned to capitalize on important opportunities in its next evolutionary phase. Further, Brake has personally championed Genomma's significant progress related to ESG, including the Company's 2025 Sustainability Vision and Commitments.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.